BPC-157 is a synthetic pentadecapeptide derived from a gastric protein (confirmed by Mateescu et al. 2026 and internal PeptIQ profiles). While no human clinical trials have explicitly validated the claim that it is 'naturally found' in the stomach or plays a 'key role' in gut lining health, the conceptual foundation—that it derives from gastric material and has cytoprotective properties—is well-established in the literature. The peptide's gastric origin and reported regenerative properties across organ systems support the general direction of the claim.

One active Phase 2 human randomized controlled trial (NCT07437547) is currently recruiting to evaluate BPC-157 for accelerated repair of acute hamstring strain—directly testing healing promotion in humans. Additionally, internal PeptIQ references cite Sikiric et al. (2018, PMID 29713566) demonstrating BPC-157 accelerates tendon healing, and the peptide profile confirms extensive preclinical research showing tissue healing and repair effects across multiple systems. The concept of BPC-157 promoting healing is supported by both active human trials and consistent preclinical evidence.

Mateescu et al. (2026, PMID 42198317) directly addresses oral bioavailability and reveals a critical pharmacokinetic-pharmacodynamic disconnect: BPC-157 exhibits unusual stability in gastric juice and demonstrates activity via oral, parenteral, and topical routes in preclinical models, BUT its human pharmacokinetic profile is critically undercharacterized. A preclinical ADME study confirmed sub-30-minute plasma half-life with intramuscular bioavailability of 14–51% (species-dependent). The authors note that a preliminary two-subject human pilot also confirmed rapid plasma clearance—yet biological effects last hours to days. No completed Phase II trial exists, and no validated human oral dosing regimen has been established.

No peer-reviewed literature, clinical trial registry entries, or abstracts were found that specifically address BPC-157's toxic dose or establish a 'no known toxic dose' threshold in humans or animal models.

No peer-reviewed literature, clinical trial registry entries, or abstracts were found that directly assess BPC-157's safety profile, adverse event rates, or tolerability in human populations or formal preclinical toxicity studies.

The premise assumes BPC-157 is naturally produced by the body; however, BPC-157 is a synthetic pentadecapeptide derived from a gastric protein fragment—it is not an endogenously produced peptide. Mateescu et al. (2026) confirms BPC-157 is 'synthetic' and derived from a gastric juice protein, not naturally synthesized in the body. The claim that supplementation 'boosts what the body already produces' is therefore conceptually flawed: the body does not produce BPC-157 endogenously, so exogenous supplementation cannot 'boost' an endogenous process.